EE200100529A - Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid - Google Patents

Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid

Info

Publication number
EE200100529A
EE200100529A EEP200100529A EEP200100529A EE200100529A EE 200100529 A EE200100529 A EE 200100529A EE P200100529 A EEP200100529 A EE P200100529A EE P200100529 A EEP200100529 A EE P200100529A EE 200100529 A EE200100529 A EE 200100529A
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
polymorphic forms
antidiabetic agent
Prior art date
Application number
EEP200100529A
Other languages
English (en)
Estonian (et)
Inventor
Reddy Gaddam Om
Kumar Potlapally Rajender
Sirisilla Raju
Krishnamurthi Vyas
Rao Dharmaraja Sreenivasa
Sarma Mamillapalli Ramabhadra
Original Assignee
Dr. Reddy's Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/000681 external-priority patent/WO2000063191A1/en
Application filed by Dr. Reddy's Research Foundation filed Critical Dr. Reddy's Research Foundation
Publication of EE200100529A publication Critical patent/EE200100529A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
EEP200100529A 1999-04-16 2000-04-17 Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid EE200100529A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB1999/000681 WO2000063191A1 (en) 1999-04-16 1999-04-16 Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
IN436MA1999 1999-04-19
PCT/IB2000/000470 WO2000063192A1 (en) 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
EE200100529A true EE200100529A (et) 2002-12-16

Family

ID=26318745

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100529A EE200100529A (et) 1999-04-16 2000-04-17 Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid

Country Status (17)

Country Link
EP (1) EP1171430A1 (pt)
CN (1) CN1351597A (pt)
AU (1) AU3831300A (pt)
BG (1) BG106022A (pt)
BR (1) BR0010683A (pt)
CA (1) CA2370401A1 (pt)
CZ (1) CZ20013711A3 (pt)
EE (1) EE200100529A (pt)
HR (1) HRP20010748A2 (pt)
HU (1) HUP0200758A3 (pt)
IL (1) IL145958A0 (pt)
MX (1) MXPA01010472A (pt)
NO (1) NO20015016L (pt)
PL (1) PL351492A1 (pt)
RU (1) RU2001130883A (pt)
TR (1) TR200103851T2 (pt)
WO (1) WO2000063192A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253353T3 (es) 2000-03-08 2006-06-01 Novo Nordisk A/S Reduccion del colesterol serico.
US6897199B2 (en) * 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
EP1505066B1 (en) * 2002-04-19 2006-12-06 Faes Farma, S.A. Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2004101505A1 (en) 2003-05-14 2004-11-25 Novo Nordisk A/S Novel compounds for treatment of obesity
EP1670815A2 (en) 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortin receptor agonists
EP2298337B1 (en) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
US20080113944A1 (en) 2004-05-04 2008-05-15 Novo Nordisk A/S Novel Indole Derivatives
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
EP1824835A1 (en) 2004-12-03 2007-08-29 Novo Nordisk A/S Heteroaromatic glucokinase activators
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
EP1904467B1 (en) 2005-07-14 2013-05-01 Novo Nordisk A/S Urea glucokinase activators
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
CN101410385B (zh) 2006-03-28 2011-08-24 高点制药有限责任公司 具有组胺h3受体活性的苯并噻唑类
EP2402324A1 (en) 2006-05-29 2012-01-04 High Point Pharmaceuticals, LLC Benzodioxolylcyclopropylpiperazinylpyridazines
EP2086951B1 (en) 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
ATE523497T1 (de) 2006-11-15 2011-09-15 High Point Pharmaceuticals Llc Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
EP2552951A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
RU2013145013A (ru) 2011-03-28 2015-05-10 Ново Нордиск А/С Новые аналоги глюкагона
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
EP2986313B1 (en) 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US20200223889A1 (en) 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
IN182496B (pt) * 1996-02-20 1999-04-17 Reddy Research Foundation
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2746099B1 (fr) * 1996-03-13 1998-04-30 Procede ameliore pour la preparation de derives de l'acide 3-(10-phenothiazyl)-propanoique ou 3-(10-phenoxazyl)-propanoique
JP2000511875A (ja) * 1996-06-19 2000-09-12 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病活性を増強されたトログリタゾンの新規な多形型及びそれらの製造方法
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP1051403A1 (en) * 1998-01-29 2000-11-15 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2002507543A (ja) * 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物

Also Published As

Publication number Publication date
BR0010683A (pt) 2003-07-01
NO20015016D0 (no) 2001-10-15
MXPA01010472A (es) 2002-05-06
IL145958A0 (en) 2002-07-25
PL351492A1 (en) 2003-04-22
HRP20010748A2 (en) 2003-02-28
EP1171430A1 (en) 2002-01-16
NO20015016L (no) 2001-12-11
HUP0200758A2 (hu) 2002-07-29
RU2001130883A (ru) 2004-03-20
BG106022A (bg) 2002-04-30
WO2000063192A1 (en) 2000-10-26
AU3831300A (en) 2000-11-02
CA2370401A1 (en) 2000-10-26
CZ20013711A3 (cs) 2002-07-17
CN1351597A (zh) 2002-05-29
HUP0200758A3 (en) 2003-07-28
TR200103851T2 (tr) 2002-04-22

Similar Documents

Publication Publication Date Title
EE200100529A (et) Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE04673B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
EE04799B1 (et) Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE200000791A (et) Uudsed atsüülpseudopeptiidid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid
EE200200149A (et) Kinasoliinühendid ja neid sisaldavad ravimkoostised
EE200100484A (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid,ja nende valmistamise meetodid
EE04276B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
EE200000168A (et) Karboksamidotiasoolderivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE200200138A (et) Kinolüülpropüülpiperidiini derivaadid, nende valmistamine ja neid sisaldavad kompositsioonid
EE200300046A (et) Asabitsüklilised ühendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EE200100495A (et) Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim
EE200200065A (et) 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon
EE200300080A (et) Polüarüülkarboksamiidühendid, nende valmistamine ja kasutamine lipiiditaset alandavate toimeainetena ning neid sisaldav farmatseutiline kompositsioon
PT1066027E (pt) Composicao farmaceutica de topiramato
EE200200409A (et) 1,3-dihüdro-2H-indool-2-ooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
EE200100259A (et) Moksifloksatsiini farmatseutiline preparaat
HUP0201334A3 (en) Hydrochloride of fused-heterocycle compound and pharmaceutical compositions containing the same
EE04015B1 (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nendevalmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE200200105A (et) Radiofarmatseutilised saadused ja nende valmistamise meetod
EE200100653A (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
EE200300234A (et) Bifenüülkarboksamiidühendite kasutamine lipiiditaset alandavate toimeainetena, meetod nende valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
EE200200022A (et) Aminotiasooli derivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE03395B1 (et) Bensotiasolooni derivaadid, protsessid ja kasutatud vaheühendid nende saamiseks ning neid sisaldavad ravimkoostised
EE200000421A1 (et) Uued pentasahhariidid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid